StemCells, Inc. Reports Positive Interim Data from Spinal Cord Injury Trial StemCells, Inc. announced that interim six-month data from the first patient cohort in the company’s phase I/II clinical trial of its proprietary HuCNS-SC® product candidate for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. [StemCells, Inc.] Press Release Anne-Marie Duliege Appointed to Governing Board of California’s Stem Cell Agency Anne-Marie Duliege, MD, Chief Medical Officer of Affymax Inc., has been appointed to the Independent Citizens Oversight Committee, the governing board of California’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine] Press Release |